Report of Foreign Issuer (6-k)
May 29 2018 - 7:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
May 29, 2018
Commission File Number: 001 - 38178
Zealand Pharma A/S
(Exact Name of Registrant as Specified in Its Charter)
Smedeland 36
2600 Glostrup (Copenhagen)
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
o
Furnished as Exhibit 99.1 to this Report on Form 6-K is a company announcement of Zealand Pharma A/S or the Company, dated May 28, 2018, announcing the completion of the second and pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Zealand Pharma A/S
|
|
|
|
|
|
By:
|
/s/ Mats Blom
|
|
|
|
|
|
|
|
Name:
|
Mats Blom
|
|
|
|
Title:
|
Chief Financial Officer
|
Date: May 29, 2018
2
EXHIBIT INDEX
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Company announcement dated May 28, 2018
|
3
Zealand Pharma AS (PK) (USOTC:ZLDPF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zealand Pharma AS (PK) (USOTC:ZLDPF)
Historical Stock Chart
From Apr 2023 to Apr 2024
